Skip to main content

Branded

  • FDA approves Strativa's Nascobal spray

    WOODCLIFF LAKE, N.J. — Strativa Pharmaceutical, a division of Par Pharmaceutical Cos., announced that the Food and Drug Administration approved Nascobal, a prescription B-12 supplement administered once a week as one spray.

  • QS/1 partnering with VUCA Health to offer on-demand prescription-specific videos

    SPARTANBURG, S.C. — QS/1, a complete healthcare automation solutions provider, on Tuesday announced it is partnering with VUCA Health to offer on-demand prescription-specific videos, as well as other services to engage patients and strengthen customer relationships.

    QS/1 pharmacies will be able to print QR codes on prescription labels that link to thousands of videos in the MedsOnCue library. The videos help patients review how to take their medications safely with easy to understand information on potential side effects and how to limit any avoidable reactions.

  • New York approves cannabidiol trial in children diagnosed with epilepsy

    NEW YORK — New York Gov. Andrew Cuomo last week announced an agreement between New York State and GW Pharmaceuticals to develop clinical trials using an active ingredient derived from the marijuana plant to help treat children diagnosed with epilepsy who suffer from seizures and other medical complications. New York will be the second state in the nation to initiate trials for the extract, known as cannabidiol, for children whose medical conditions have not been successfully treated by other methods.

  • Study: Almost half of all narcotic prescriptions written by 5% of opioid prescribers

    SAN DIEGO — As many as 40% of U.S. narcotic prescriptions in 2011-2012 were written by only 5% of opioid prescribers, according to a study Express Scripts presented Monday at AcademyHealth's annual research meeting.

    The study identifies prescribers who prescribe opioids at a much higher rate than peers who are in the same specialty, treat patients of similar age and practice in the same geographic region. Express Scripts' multivariate approach to identifying high prescribers is the first of its kind, the company noted.

  • Government outlines what electronic health records should look like over next 10 years

    WASHINGTON — The Office of the National Coordinator for Health Information Technology last week issued a policy paper, "A 10-Year Vision to Achieve an Interoperable Health IT Infrastructure," which outlines the government's pledge to support interoperable electronic health records to most Americans. 

    America is three-quarters of the way there. 

  • Bayer HealthCare names Dieter Weinand president effective Aug. 1

    LEVERKUSEN, Germany — Bayer last week named Dieter Weinand president of Bayer HealthCare Pharmaceuticals effective Aug. 1. At that time, he also will join the executie committee of Bayer HealthCare. 

    "We welcome Dieter Weinand to our management team," said Olivier Brandicourt, Bayer HealthCare CEO. "Based on his extensive commercial experience in the pharmaceutical industry, Dieter Weinand will drive the growth of our pharmaceutical business further and maximize the value of our product portfolio." 

  • FDA approves expanded label for Teva's Azilect

    JERUSALEM — Teva on Monday announced that the Food and Drug Administration approved an expanded label for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include dopamine agonists. The approval reflects that Azilect can be used alone or with other Parkinson's disease medications.

  • Merck to acquire Idenix Pharmaceuticals for $3.9 billion

    WHITEHOUSE STATION, N.J. — Merck and Idenix Pharmaceuticals on Monday announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.9 billion, has been approved by the boards of directors of both companies.

X
This ad will auto-close in 10 seconds